Detection of Fusions: Merits and Limitations of Current Diagnostic Platforms.

Cancer Res 2019 Jul 13;79(13):3163-3168. Epub 2019 Jun 13.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Oncogenic fusions involving , and with various partners are diagnostic of infantile fibrosarcoma and secretory carcinoma yet also occur in lower frequencies across many types of malignancies. Recently, targeted small molecular inhibitor therapy has been shown to induce a durable response in a high percentage of patients with fusion-positive cancers, which has made the detection of fusions critical. Several techniques for fusion diagnosis exist, including pan-Trk IHC, FISH, reverse transcription PCR, DNA-based next-generation sequencing (NGS), and RNA-based NGS. Each of these assays has unique features, advantages, and limitations, and familiarity with these assays is critical to appropriately screen for fusions. Here, we review the details of each existing methodology.

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-0372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606326PMC
July 2019
3 Reads

Publication Analysis

Top Keywords

detection fusions
8
durable response
4
assays unique
4
induce durable
4
response high
4
high percentage
4
rna-based ngs
4
percentage patients
4
therapy induce
4
ngs assays
4
unique features
4
transcription pcr
4
targeted small
4
malignancies targeted
4
small molecular
4
features advantages
4
inhibitor therapy
4
molecular inhibitor
4
patients fusion-positive
4
cancers detection
4

Altmetric Statistics

Similar Publications